FDA Grants RenovaCare Full IDE Approval for Safety and Feasibility Clinical Trial
Roseland, NJ – May 6th, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), today announced that its IDE application has been granted full approval by the FDA, enabling RenovaCare to conduct a clinical trial to evaluate the safety and feasibility of its SkinGun™ and CellMist™ System for the treatment of burn wounds.